UroGen Pharma Ltd. (URGN) Q3 2026 earnings results
UroGen Pharma Ltd. (URGN) reported Q3 2026 results on Nov 4, 2026, 8:08:03 AM ET: GAAP EPS -$0.03 vs. $0.10 expected (miss by $0.13); revenue $89.00M vs. $89.91M expected (miss by 1.0%). Outlook: Full-year 2026 JELMYTO revenue guidance updated to approximately $90 million and operating expenses expected in the range of $260 million to $270 million.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | -$0.03 | $0.10 | Miss by $0.13 |
| Revenue | $89.00M | $89.91M | Miss by 1.0% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 4, 2026, 8:08:03 AM ET. Nexqual published them 38 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Stock reaction
The results came out before the market opened. URGN closed at $28.74 on November 4, 2026, down 16.5% from its $34.40 close on November 3, 2026 before the results. Latest: $25.29 as of 11:53 AM ET, −26.5% since the pre-release close.
Questions and answers
Did UroGen Pharma Ltd. beat earnings expectations?
No. UroGen Pharma Ltd. reported GAAP EPS of -$0.03 against an average analyst estimate of $0.10 (miss by $0.13), and revenue of $89.00M against $89.91M expected (miss by 1.0%).
What were UroGen Pharma Ltd.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of -$0.03 and revenue of $89.00M.
When did UroGen Pharma Ltd. report Q3 2026 earnings?
Nov 4, 2026, 8:08:03 AM ET, in an SEC 8-K filing (Item 2.02).
How did URGN stock react to the earnings?
The results came out before the market opened. URGN closed at $28.74 on November 4, 2026, down 16.5% from its $34.40 close on November 3, 2026 before the results. Latest: $25.29 as of 11:53 AM ET, −26.5% since the pre-release close.
What did UroGen Pharma Ltd. say about its outlook?
Full-year 2026 JELMYTO revenue guidance updated to approximately $90 million and operating expenses expected in the range of $260 million to $270 million.
More on URGN
URGN stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 4, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:53 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:53 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt